Safety and Efficacy Study of CitraFleet (Sodium Picosulphate) as an Evacuating Treatment Prior to Colonoscopy.

• ClinicalTrials.gov Identifier: NCT01065857
• Recruitment Status: Completed
• First Posted: February 9, 2010
• Last Update Posted: April 15, 2011
• Sponsor: Laboratorios Casen-Fleet S.L.U.
• Collaborators: Trial Form Support S.L.; Apices Soluciones S.L.
• Information provided by: Laboratorios Casen-Fleet S.L.U.

Study Description

Brief Summary:

The purpose of this study is to determine any significant differences in the efficacy and acceptability between CitraFleet and Klean Prep® (polyethylene glycol) for the preparation of gastrointestinal subjects undergoing a colon examination.

Condition or disease	Intervention/treatment	Phase
Subjects Undergoing a Complete Exploratory Diagnostic Colonoscopy for the First Time.	Drug: Sodium picosulphate, light magnesium oxide and anhydride citric acid.; Drug: Polyethylene glycol, KCl, NaCl, sodium sulphate anhydrous and sodium bicarbonate.	Phase 3

Detailed Description:

The composite principal objective of the current study will therefore be, to determine any significant differences in the joint variable of efficacy and acceptability between CitraFleet and Klean Prep® (polyethylene glycol) for the preparation of subjects undergoing a colon examination.

The evaluation will be carried out by two blinded assessors, independent of the investigator who performed the procedure (endoscopist investigator). It will be assessed from images of different sections of the colon: cecum, ascending, transverse, descending and rectum and subsequent confirmation by Principal Investigator if an agreement has been reached between the two blinded assessors or whether it is necessary to reach consensus.

The evaluation of the subject's acceptability will be assessed using a 5 point scale which assesses the difficulty of taking the product, the degree of discomfort caused by it, and the taste of the drug.

The secondary objective is to evaluate the safety of CitraFleet.

In addition a second exploratory arm of CitraFleet was included in this study (CitraFleet Exploratory arm). The study is not powered to make formal statistical comparisons for this arm. Exploratory assessment of this arm against the main CitraFleet regimen and Klean-Prep will be made in order to run future trials design with this schedule.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 547 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Outcomes Assessor)
• Official Title: Phase III, Multicenter, Randomized, Assessor-blind Study to Evaluate the Safety and Efficacy of CitraFleet (Sodium Picosulphate) as an Evacuating Treatment Prior to Colonoscopy.
• Study Start Date: January 2010
• Actual Primary Completion Date: June 2010
• Actual Study Completion Date: February 2011

Arms and Interventions

Arm	Intervention/treatment
Experimental: Citrafleet; The day prior to the colonoscopy in two dose times, first at 15:00h and second at 20:00h.	Drug: Sodium picosulphate, light magnesium oxide and anhydride citric acid.; 2 Single-dose sachets containing sodium picosulphate (0.01g/sachet), light magnesium oxide (3.50g/sachet) and anhydrous citric acid (10.97g/sachet).; Other Name: Citrafleet
Active Comparator: Klean Prep; The day prior to the colonoscopy from 16:00h to 20:00h.	Drug: Polyethylene glycol, KCl, NaCl, sodium sulphate anhydrous and sodium bicarbonate.; 4 sachets containing Polyethylene glycol 3350 (59 gr), KCl (0.7425 gr), NaCl (1.465 gr), sodium sulphate anhydrous (5.685 gr), sodium bicarbonate (1.685 gr).; Other Name: KleanPrep PEG 4l
Experimental: Citrafleet Exploratory; The day of the colonoscopy in two dose times, first at 06:00h and second at 09:00h.	Drug: Sodium picosulphate, light magnesium oxide and anhydride citric acid.; 2 Single-dose sachets containing sodium picosulphate (0.01g/sachet), light magnesium oxide (3.50g/sachet) and anhydrous citric acid (10.97g/sachet).; Other Name: Citrafleet

Outcome Measures

Primary Outcome Measures :

1. Percentage of subjects that achieve 'excellent' or 'good' cleansing in the Fleet® Grading Scale for Bowel Cleansing. [ Time Frame: 24 hours ]
2. Percentage of subjects who find the agent easy to take or tolerable using a 5 point scale which assesses, the difficulty of taking the product, the degree of discomfort caused by it, and the taste of the drug, recorded in the subject questionnaire [ Time Frame: 24 hours ]

Secondary Outcome Measures :

1. Frequency of adverse reactions. [ Time Frame: 24 hours ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Subjects who are between 18 and 80 years of age.
• Subjects undergoing complete colonoscopy and therefore require prior preparation with either Klean Prep® or CitraFleet.
• Subjects capable of maintaining appropriate oral hydration during the intestinal preparation process.
• Subjects that have provided written informed consent.
• Subjects in whom the use of any of the study drugs (KleanPrep®,CitraFleet) is not contraindicated.
• Subjects who can communicate with the study personnel and comply with study requirements.
• Subjects undergoing a complete exploratory diagnostic colonoscopy for the first time.

Exclusion Criteria:

• Severe renal insufficiency.
• Ascites.
• Congestive heart failure.
• Gastrointestinal obstruction, gastric retention, intestinal perforation and/or ileus.
• Megacolon and/or toxic colitis.
• Nausea and/or vomiting and/or abdominal pain.
• Severe dehydration.
• Hypermagnesemia.
• Rhabdomyolysis.
• Pregnant women.
• Subjects who have participated in a clinical trial in the previous 30 days.
• Abdominal surgery for any acute process (for example acute appendicitis).
• Active inflammatory intestinal disease.
• Known allergy to any of the active ingredients or excipients of the study drugs.
• Subjects not providing written informed consent.
• Subjects not complying with all of the inclusion criteria.

Contacts and Locations

Locations

Spain

H. Infanta Elena

Valdemoro, Madrid, Spain, 28340

Clínica Universitaria de Navarra

Pamplona, Navarra, Spain, 31008

H. Universitario de Canarias

La Laguna, Tenerife, Spain, 38320

H. Basurto

Bilbao, Vizcaya, Spain, 48013

H. Universitari Vall´d Hebron

Barcelona, Spain, 08035

H. Clínic

Barcelona, Spain, 08036

H. General Universitario Reina Sofía

Córdoba, Spain, 14004

H. Universitario Virgen de las Nieves

Granada, Spain, 18014

H. General Universitario Gregorio Marañón

Madrid, Spain, 28007

H. Universitario Puerta de Hierro

Madrid, Spain, 28222

H. Universitario Virgen de la Arrixaca

Murcia, Spain, 30120

H. Regional Universitario Carlos Haya

Málaga, Spain, 29010

H. Universitario Central de Asturias

Oviedo, Spain, 33006

H. Virgen Macarena

Sevilla, Spain, 41009

H. Universitario La Fé

Valencia, Spain, 46009

Sponsors and Collaborators

Laboratorios Casen-Fleet S.L.U.

Trial Form Support S.L.

Apices Soluciones S.L.

Investigators

• Principal Investigator: Miguel A. Muñoz-Navas, M.D.; Clínica Universitaria de Navarra

More Information

• Responsible Party: Ángel Navarro Lima, M.D. / European Medical Affairs Director, Laboratorios Casen-Fleet S.L.U.
• ClinicalTrials.gov Identifier: NCT01065857
• Other Study ID Numbers: CF-PICOS2006
• First Posted: February 9, 2010
• Last Update Posted: April 15, 2011
• Last Verified: April 2011

Keywords provided by Laboratorios Casen-Fleet S.L.U.:

Colonoscopy, Preparation, Evacuating, Bowel Cleansing.

Additional relevant MeSH terms:

Picosulfate sodium; Sodium sulfate; Magnesium Oxide; Citric Acid; Sodium Citrate; Anticoagulants; Calcium Chelating Agents; Chelating Agents; Sequestering Agents; Molecular Mechanisms of Pharmacological Action; Cathartics; Gastrointestinal Agents; Antacids